The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:wherein:A is C1-6alkyl C3-6cycloalkyl —CH2—R6 —CHMe-R7 —CMe2-R7 or optionally substituted aryl; wherein when A is optionally substituted aryl said aryl group is optionally substituted with 1 to 3 substituents which may be the same or different selected from the group consisting of halogen C1-6alkyl —CF3 C1-4alkoxy C1fluoroalkoxy cyano NR8R9 and pyridyl wherein the pyridyl is optionally substituted by o...

This invention relates to modulation of the α7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a salt thereof Formula (I).

The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent wherein the second therapeutic agent is selected from:(a) a therapeutic agent known to modify cholinergic transmission such as M1 muscarinic receptor agonists or allosteric modulators M2 muscarinic antagonists acetylcholinesterase inhibitors nicotinic receptor agonists or allosteric modulators 5-HT4 receptor partial agonists or 5HT1A receptor antagonists a...

The present invention relates to novel piperazine derivatives (I) with affinity for Ca.sub.v2.2 calcium channels and which are capable of interfering with Ca.sub.v2.2 calcium channels; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy.

Pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth and methods of using them are provided.

The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazineor a pharmaceutically acceptable salt thereof in particular the hydrochloride salt thereof and crystalline forms of the hydrochloride salt; to processes for the preparation of the compound or its salt; to compositions containing it; and to its use in the treatment or prophylaxis of neurological or psychiatric diseases such as cognitive impairment fatigue or a sleep disorder for example...